IOVA Iovance Biotherapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

IOVA [NASD]

Iovance Biotherapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.93	Insider Own	0.20%	Shs Outstand	133.16M	Perf Week	0.03%
Market Cap	5.38B	Forward P/E	-	EPS next Y	-2.13	Insider Trans	0.00%	Shs Float	116.22M	Perf Month	18.69%
Income	-245.70M	PEG	-	EPS next Q	-0.46	Inst Own	-	Short Float	11.12%	Perf Quarter	29.03%
Sales	-	P/S	-	EPS this Y	-25.10%	Inst Trans	0.06%	Short Ratio	9.25	Perf Half Y	2.76%
Book/sh	5.69	P/B	6.62	EPS next Y	-9.80%	ROA	-53.20%	Target Price	43.36	Perf Year	85.65%
Cash/sh	5.40	P/C	6.97	EPS next 5Y	-	ROE	-59.40%	52W Range	18.70 - 41.49	Perf YTD	36.02%
Dividend	-	P/FCF	-	EPS past 5Y	-27.00%	ROI	-	52W High	-9.26%	Beta	0.97
Dividend %	-	Quick Ratio	14.30	Sales past 5Y	-	Gross Margin	-	52W Low	101.34%	ATR	1.79
Employees	148	Current Ratio	14.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	64.00	Volatility	4.01% 5.47%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-23.00%	Profit Margin	-	Rel Volume	0.60	Prev Close	36.75
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 06 AMC	Payout	-	Avg Volume	1.40M	Price	37.65
Recom	1.70	SMA20	13.64%	SMA50	16.80%	SMA200	23.86%	Volume	838,671	Change	2.45%

Oct-06-20

Downgrade

Wells Fargo

Overweight → Equal Weight

Apr-22-20

Initiated

Mizuho

Buy

$61

Mar-04-20

Initiated

Barclays

Overweight

$45

Feb-26-20

Reiterated

Oppenheimer

Outperform

$32 → $35

Feb-26-20

Reiterated

H.C. Wainwright

Buy

$32 → $36

Dec-18-19

Initiated

JMP Securities

Mkt Outperform

$38

Oct-01-19

Initiated

Stifel

Buy

$27

Apr-29-19

Initiated

Piper Jaffray

Overweight

$20

Feb-28-19

Reiterated

Chardan Capital Markets

Buy

$30 → $20

Feb-07-19

Initiated

Robert W. Baird

Outperform

Dec-31-18

Resumed

B. Riley FBR

Buy

$24

Jul-06-18

Reiterated

Chardan Capital Markets

Buy

Apr-10-18

Upgrade

B. Riley FBR, Inc.

Neutral → Buy

$22

Mar-13-18

Reiterated

B. Riley FBR, Inc.

Neutral

$18.50 → $22

Feb-23-18

Downgrade

B. Riley FBR, Inc.

Buy → Neutral

$18 → $18.50

Jan-25-18

Reiterated

H.C. Wainwright

Buy

$16 → $22

Nov-01-17

Reiterated

B. Riley FBR, Inc.

Buy

$17.50 → $18

Oct-14-20 05:01PM	Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting GlobeNewswire +6.66%
Oct-09-20 10:12PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA PR Newswire +6.02%
09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi, Iovance Biotherapeutics, and Y-mAbs Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire
Oct-08-20 05:48PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA PR Newswire
04:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Iovance Biotherapeutics, Inc. (IOVA) Investigation ACCESSWIRE
Oct-07-20 10:49AM	Iovance Stock Down on Delay in Filing for Melanoma Candidate Zacks
Oct-06-20 09:43AM	Iovance Shares Tumble After Delaying FDA Cancer Drug Application TheStreet.com -12.35%
08:24AM	The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation Benzinga
07:57AM	Iovance's stock tumbles over questions about regulatory submission for melanoma drug MarketWatch
07:00AM	Iovance Biotherapeutics to Present at Upcoming October Conferences GlobeNewswire
Oct-05-20 04:01PM	Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma GlobeNewswire
Sep-07-20 03:46PM	Iovance Biotherapeutics (NASDAQ:IOVA) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
12:54PM	Hedge Funds Cant Buy Enough Of Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
Sep-05-20 11:32AM	Iovance Biotherapeutics (IOVA) Down 1.6% Since Last Earnings Report: Can It Rebound? Zacks
Aug-10-20 11:22AM	Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus Zacks
Aug-07-20 07:30AM	Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020 GlobeNewswire -6.20%
Aug-06-20 04:01PM	Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update GlobeNewswire
Aug-04-20 05:33PM	Lion Biotechnologies Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Jul-23-20 07:30AM	Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020 GlobeNewswire
Jul-15-20 01:15PM	Steven Cohen Homes in on Otonomy GuruFocus.com
Jul-14-20 12:49PM	Were Hedge Funds Right About Iovance Biotherapeutics, Inc. (IOVA)? Insider Monkey
Jul-01-20 07:11AM	Is Iovance Biotherapeutics a Buy? Motley Fool +5.76%
Jun-08-20 04:01PM	Iovance Biotherapeutics to Present at Upcoming June Conferences GlobeNewswire
Jun-04-20 11:31AM	Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report? Zacks
Jun-02-20 04:01PM	Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering GlobeNewswire
12:00PM	Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know Zacks
Jun-01-20 09:20AM	Hedge Funds Arent Done Buying Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
May-29-20 08:01AM	Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program GlobeNewswire
May-28-20 09:30PM	Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock GlobeNewswire -14.26%
04:35PM	A Public Offering Undercut This Biotech Stock's Promising Cancer Data Investor's Business Daily
01:28PM	Iovance Biotherapeutics Couples Data Release With Stock Offering Motley Fool
11:02AM	Why Iovance Biotherapeutics Is Trading Lower Today Benzinga
May-27-20 04:20PM	Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
04:01PM	Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma GlobeNewswire
May-13-20 05:01PM	Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma GlobeNewswire -5.15%
May-11-20 11:13PM	JPMorgan Genetic-Therapies Fund Finds Success in Covid-19 Era Bloomberg
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace +6.90%
May-06-20 11:26AM	Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil Zacks
07:04AM	Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript Motley Fool
May-05-20 04:01PM	Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update GlobeNewswire
Apr-30-20 06:13PM	Gilead, Takeda Rumored to Have Sights on Iovance GuruFocus.com
08:33AM	3 Monster Growth Stocks With Still Plenty of Gas in the Tank TipRanks
Apr-29-20 12:01PM	Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program GlobeNewswire
Apr-27-20 04:01PM	Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020 GlobeNewswire
Apr-17-20 08:43AM	Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't? Zacks
Apr-16-20 04:11PM	In cancer-fighting buying spree, Gilead said to eye East Bay biotech American City Business Journals
Apr-13-20 05:14PM	Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 GlobeNewswire -5.18%
Mar-27-20 02:55PM	Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
Mar-11-20 09:18AM	Are Options Traders Betting on a Big Move in Iovance Biotherapeutics (IOVA) Stock? Zacks -7.36%
Mar-10-20 08:23AM	Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price? Simply Wall St.
Mar-02-20 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire +9.36%
Feb-25-20 05:46PM	Report: Peninsula cell therapy company explores sale American City Business Journals +27.42%
04:01PM	Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-19-20 07:00AM	Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020 GlobeNewswire
Feb-12-20 07:00AM	Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences GlobeNewswire
Jan-15-20 08:00AM	Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel GlobeNewswire
Jan-13-20 04:15PM	Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs Investor's Business Daily -11.86%
Jan-12-20 04:30PM	Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog GlobeNewswire
Dec-26-19 11:25AM	How Did Iovance Biotherapeutics, Inc. (IOVA) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Dec-23-19 05:40AM	Wall Street Roundup: Analysts Make Moves on These 3 Stocks TipRanks
Dec-16-19 03:55PM	5 Health Care Stocks Gurus Are Buying GuruFocus.com +5.20%
Dec-04-19 08:03PM	Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
05:17AM	We Think Iovance Biotherapeutics (NASDAQ:IOVA) Can Afford To Drive Business Growth Simply Wall St.
Dec-02-19 07:00AM	Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December GlobeNewswire
Nov-21-19 07:00AM	Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy GlobeNewswire
Nov-08-19 02:58PM	The Unloved Biotechnology ETF Rally ETF Trends +14.33%
07:00AM	Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting GlobeNewswire
Nov-07-19 04:32PM	Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November GlobeNewswire
Nov-04-19 04:01PM	Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results GlobeNewswire -6.87%
Oct-31-19 04:43PM	Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019 GlobeNewswire
Oct-21-19 10:55AM	Hedge Funds Are Dumping Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
Oct-02-19 07:00AM	Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting GlobeNewswire +6.86%
Oct-01-19 01:48PM	Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio Benzinga
Sep-27-19 04:30PM	Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire
Sep-19-19 02:07PM	Have Insiders Been Buying Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares This Year? Simply Wall St.
Sep-16-19 12:00PM	Iovance Biotherapeutics: Technical Analysis and Strategy TheStreet.com
Aug-27-19 04:57PM	Iovance Biotherapeutics: Buy the Dip? Motley Fool
Aug-26-19 04:30PM	Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-14-19 01:04PM	IOVA Stock Could See Another Massive Rebound Schaeffer's Investment Research
Aug-02-19 10:24PM	Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript Motley Fool -5.76%
04:28PM	Biotech Merger Activity Has Been Hot In 2019 So, What's One More? Investor's Business Daily
Aug-01-19 04:01PM	Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-29-19 03:00PM	3 Top Biotech Stocks to Buy Right Now Motley Fool
Jul-26-19 07:00AM	Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019 GlobeNewswire
Jul-18-19 08:00AM	Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer GlobeNewswire +5.31%
Jul-10-19 12:46PM	Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price? Simply Wall St.
Jul-08-19 06:22PM	Here's Why Iovance Biotherapeutics Soared 50% in June Motley Fool
Jul-02-19 08:50AM	Iovance stock up 2% after company gives positive regulatory update on potential cervical cancer treatment MarketWatch
07:30AM	Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) GlobeNewswire
Jun-25-19 09:21AM	3 Stocks With a Perfect Smart Score TipRanks
Jun-24-19 03:00PM	3 Top Healthcare Stocks to Buy Right Now Motley Fool
Jun-19-19 01:58PM	Harry Boxers three biotech stocks on the move include Nektar Therapeutics MarketWatch
Jun-18-19 09:51AM	Cancer Therapy Stocks Soar After Pfizer Deal Investopedia
07:09AM	Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-17-19 03:37PM	Why Iovance Biotherapeutics Stock Jumped Today Motley Fool +14.92%
Jun-14-19 09:08AM	Did Hedge Funds Drop The Ball On Iovance Biotherapeutics, Inc. (IOVA) ? Insider Monkey
Jun-12-19 10:30AM	PHIO: Two Compounds Entering Clinic in 2020 Zacks Small Cap Research
Jun-11-19 07:00AM	Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors GlobeNewswire -5.02%
Jun-05-19 03:11PM	Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
08:00AM	Iovance and Amgen Are Making Cancer History Bloomberg

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience